Aarti Pharmalabs gains on commissioning phase 1 of new Gujarat facility

According to an exchange filing, the company confirmed that it has received all necessary approvals and permissions to commence operations at the site. Phase 1 includes a total reactor capacity of 440 kilolitres (kL), with 63 reactors.

The greenfield facility spans 80 acres and is designed for significant scalability, with potential to expand capacity up to 8'10 times that of Phase 1 in the future.

Aarti Pharmalabs (APL) is an established, internationally recognized manufacturer of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, new chemical entities (NCEs), and xanthine derivatives based in India.

The company reported a 10.73% decline in consolidated net profit to Rs 49.50 crore in Q1 FY26, compared to Rs 55.45 crore posted in Q1 FY25. Revenue from operations slumped 30.47% YoY to Rs 386.19 crore in the quarter ended 30 June 2025.

Powered by Capital Market - Live News